Central Type 2 Corticotropin-Releasing Hormone Receptor Mediates Hypothalamic-Pituitary-Adrenocortical Axis Activation in the Rat
Authors:
- Hiroshi MaruyamaHMHiroshi Maruyama
- Kozo HashimotoKHKozo Hashimoto
- 4 June 2007
- journal article
- research article
- Published by S. Karger AG in Neuroendocrinology
- Vol. 86 (1) , 1-16
Abstract
In an attempt to clarify the role of the type 2 corticotropin-releasing hormone (CRH) receptor (CRHR-2) in the brain in activation of the hypothalamic-pituitary-adrenocortical axis, we conducted experiments using male Wistar rats. First, an injection of urocortin-2 (7.5 µg) into the lateral ventricle resulted in transient increases in CRH heteronuclear RNA (hnRNA) in parvocellular paraventricular nucleus (PVN) and in plasma adrenocorticotropic hormone (ACTH), whereas sustained increases in arginine vasopressin (AVP) hnRNA and c-fos mRNA in the parvocellular PVN were observed as compared with vehicle treatment. Pretreatment with the selective CRHR-2 antagonist antisauvagine-30 (20 µg) into the lateral ventricle 15 min prior to agonist injection attenuated the stimulatory effects of urocortin-2 on the above-mentioned hypothalamic-pituitary-adrenal axis variables. These effects were similar or rather more potent than those induced by pretreatment with 50 µg of α-helical CRH. Second, we found longer-lasting increases in CRH and AVP hnRNA and c-fos mRNA in parvocellular PVN and in plasma ACTH following central administration of urocortin-3 (7.5 µg) than following urocortin-2. Pretreatment with antisauvagine-30 antagonized the effects of urocortin-3 on the above-mentioned variables. Finally, central administration of antisauvagine-30 as well as α-helical CRH profoundly attenuated restraint-stress-induced increases in AVP hnRNA. However, α-helical CRH, but not antisauvagine-30, attenuated restraint-stress-induced increases in CRH hnRNA in the PVN. Both antagonists transiently attenuated stress responses of c-fos mRNA in PVN and plasma ACTH. These results indicate that there is a CRHR-2-mediated mechanism in the brain that stimulates CRH- and AVP-producing neurons in the PVN which results in the promotion of plasma ACTH secretion.Keywords
This publication has 64 references indexed in Scilit:
- Corticotropin-releasing factor receptors 1 and 2 in anxiety and depressionCurrent Opinion in Pharmacology, 2002
- Identification of urocortin III, an additional member of the corticotropin-releasing factor (CRF) family with high affinity for the CRF2 receptorProceedings of the National Academy of Sciences, 2001
- Human stresscopin and stresscopin-related peptide are selective ligands for the type 2 corticotropin-releasing hormone receptorNature Medicine, 2001
- Animal models of CRH excess and CRH receptor deficiency display altered adaptations to stressPeptides, 2001
- Urocortin II: A member of the corticotropin-releasing factor (CRF) neuropeptide family that is selectively bound by type 2 CRF receptorsProceedings of the National Academy of Sciences, 2001
- Corticotropin Releasing Factor Receptor 1–Deficient Mice Display Decreased Anxiety, Impaired Stress Response, and Aberrant Neuroendocrine DevelopmentNeuron, 1998
- Urocortin, a mammalian neuropeptide related to fish urotensin I and to corticotropin-releasing factorNature, 1995
- Identification of a second corticotropin-releasing factor receptor gene and characterization of a cDNA expressed in heart.Proceedings of the National Academy of Sciences, 1995
- Cloning and characterization of a functionally distinct corticotropin-releasing factor receptor subtype from rat brain.Proceedings of the National Academy of Sciences, 1995
- Cloning and functional expression of a rat brain corticotropin releasing factor (CRF) receptorEndocrinology, 1993